In this analysis, physicians, despite guideline recommendations, chose to treat patients with mild persistent asthma more often with LM and ICS+LABA than with ICS. However, therapy with ICS was less costly than treatment with either LM or ICS+LABA, primarily due to differences in drug costs, and provided similar outcomes.

No abstract

Results indicate that receipt of BDP-HFA, compared with receipt of FP, is associated with a decreased probability of ER visits or asthma-related ER visits and higher odds of reaching a medical possession ratio threshold of 50% or 75%. Receipt of BDP-HFA was also associated with lower total drug costs and lower total medical costs.

dex scores have been slightly increased from 0.94 to 0.96 during 2007-2010. Male adults had higher EQ-5D index scores than female (0.96 vs. 0.92). Elderly (ageՆ60) had significantly lower EQ-5D index scores (score ranges: 0.02 to 0.11) than young adult (ageϭ19-29) after adjusting for other variables. EQ-5D index scores were significantly reduced by stroke (reduced by -0.10), arthritis (reduced by -0.05), cardiovascular disease (reduced by -0.04), and diabetes (reduced by -0.02). CONCLUSIONS: QOL in South Korean adults was significantly reduced by chronic diseases and age. Despite national efforts to detect and treat chronic diseases at early stage of disease, significant reduction in QOL due to chronic diseases still exist. It is emphasized the need for implementation of effective public health programs for decreased prevalence of chronic diseases. OBJECTIVES:In a real world setting, to design a system to measure the effect of fluctuating symptoms (problem periods) by capturing information on days of the largest and smallest impact. METHODS: The evaluation was conducted throughout the UK using a web-based system -PROBE (patient reported outcome based evaluation). We investigated women reporting problems with their periods. The issues in setting out and programming the study design were a) determining the day on which they would suffer the greatest impact, b) duration of impact c) predicting when the normal data could be collected. Variability exists between woman to woman and between cycles for each woman. The problems were addressed by an initial screening questionnaire, which determined time between menses, length of menses, regularity of menstrual cycle and date of next menses so that questionnaires could be sent out on the appropriate days. 5 consecutive days of questionnaires were completed during menses and 3 consecutive days between menses. Measures included demographic data, symptoms, previous treatments, current medications, absenteeism, presenteeism, HRQoL using SF 36 and EQ 5D. RESULTS: Target numbers were 2000 for the screening questionnaire and 200 for the main survey, in reality 2699 women participated in the screening questionnaire with 331 in the main survey. 165 women completed the survey at both the time of menses and between menses allowing a direct comparison of their reported outcomes. On the validated questionnaires the data quality was high as reported by the Copyright holders. Significant findings were obtained on the primary and secondary measures. CONCLUSIONS: This evaluation shows that a web based survey system (PROBE methodology) is flexible, interactive and reliable in obtaining patient reported outcomes in a condition with fluctuating symptoms. OBJECTIVES: 1) To evaluate the effectiveness of a Protocol for respiratory syncytial virus (RSV) immunoprophylaxis in pre-term infants born at Ͻ34 weeks gestation age (GA), and 2) To calculate economic burden in accordance with the Protocol versus labeled indication for palivizumab. METHODS: Setting: Spain/1500-bed Hospital. RSV season: Octobe...

inpatient care and drug costs represented about 50% and 27% respectively of overall expenses. The increase by 24.4% polytherapy patients mean costs as compared to monotherapy raised to 72% [IC 95: 44-106%] after adjustment on age, gender and presence of severe comorbidity. CONCLUSIONS: Polytherapy in epilepsy is associated with substantial higher direct costs. OBJECTIVES:To develop a tool to estimate the first-year per member and total health plan costs associated with monitoring of MS therapies in the United States. METHODS: Data were incorporated into an interactive tool designed to allow a health plan to estimate their costs for monitoring. MS prevalence was based on the literature. The default value for the proportion of MS patients treated with immunomodulators was assumed at 95% and adjusted IMS data were used for default market share inputs. Current Procedural Terminology (CPT) codes corresponding to the monitoring and administration procedures recommended by each product's prescribing information (PI) were identified. Charges associated with each CPT code were assigned using physician fee schedule software based on Medicare charges with default values set at 150%. PI recommendations were used for the proportion being monitored and the frequency of monitoring. In cases where a PI recommended only individuals with specific characteristics undergo monitoring, a database analysis identifying all individuals with a diagnosis of MS in the i3 InVision Data Mart (Ingenix, Eden Prairie, MN) was used to estimate the proportion of patients who may require that specific monitoring. RESULTS: The tool yielded average per patient and health plan costs expected with MS therapy monitoring. The tool conservatively estimates that the average per member first-year monitoring and administration costs ranged from $0 for glatiramer acetate to $3279 for natalizumab. Based on default values, the estimated annual costs of monitoring for all MS therapies for a million member health plan is $519,451. CONCLUSIONS: Estimating the economic impact of FDA-recommended MS therapy monitoring allows health plans to more closely assess the total cost of MS. This tool allows health plans to individualize inputs to estimate the plan-specific economic impact of MS therapy monitoring.